TABLE 1. Clinical and Procedural Characteristics of Study Patients
Characteristic | Iopamidol-370 Group (n=204) | Iodixanol-320 Group (n=210) | P* |
---|---|---|---|
Data are presented as mean±SD where appropriate. | |||
*t test for continuous variables; Fisher exact test for categorical variables. | |||
Age, y | 72.4±9.0 | 70.5±9.9 | 0.04 |
Gender, M/F | 138/66 | 127/83 | 0.15 |
Body weight, kg | 82.7±17.7 | 86.7±20.6 | 0.03 |
Body mass index, kg/m2 | 29.2±5.3 | 30.2±5.8 | 0.06 |
Contrast volume, mL | 133.7±74.4 | 136.4±71.6 | 0.70 |
Dose/body weight, gI/kg | 0.62±0.36 | 0.53±0.31 | 0.01 |
Diabetes mellitus, n (%) | 78 (38.2) | 92 (43.8) | 0.27 |
Time of postdose sampling, n (%) | |||
45 to 71 hours | 170 (83.3) | 175 (83.3) | 0.94 |
71 to 96 hours | 27 (13.2) | 29 (13.8) | |
>96 hours | 7 (3.5) | 6 (2.9) | |
Type of procedure, n (%) | |||
Dx cardioangiography | 123 (60.3) | 128 (61.0) | 0.92 |
PCI | 81 (39.7) | 82 (39.0) | |
NAC premedication, n (%) | 79 (38.7) | 89 (42.4) | 0.48 |
Intravenous volume supplementation/body weight (mL/kg) | 11.2±2.3 | 11.5±2.3 | 0.32 |
Predose eGFR (mL/min per 1.73 m2), n (%) | |||
20 to 30 | 15 (7.4) | 17 (8.1) | 0.83 |
30 to 40 | 42 (20.6) | 40 (19.1) | |
40 to 50 | 82 (40.1) | 78 (37.1) | |
50 to 59 | 65 (31.9) | 75 (35.7) |